​

Ionis Pharmaceuticals (IONS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IONS Stock Forecast

Ionis Pharmaceuticals stock forecast is as follows: an average price target of $58.33 (represents a 63.71% upside from IONS’s last price of $35.63) and a rating consensus of 'Buy', based on 18 wall street analysts offering a 1-year stock forecast.

IONS Price Target

The average price target for Ionis Pharmaceuticals (IONS) is $58.33 based on 1-year price targets from 18 Wall Street analysts in the past 3 months, with a price target range of $77.00 to $33.00. This represents a potential 63.71% upside from IONS's last price of $35.63.

IONS Analyst Ratings

Buy

According to 18 Wall Street analysts, Ionis Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for IONS stock is 0 'Strong Buy' (0.00%), 9 'Buy' (50.00%), 8 'Hold' (44.44%), 1 'Sell' (5.56%), and 0 'Strong Sell' (0.00%).

Ionis Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 09, 2024Debjit ChattopadhyayGuggenheim$65.00$37.8071.96%82.43%
Aug 02, 2024Kostas BiliourisBMO Capital$60.00$51.3216.91%68.40%
Jul 24, 2024Mani ForooharLeerink Partners$62.00$51.8619.55%74.01%
Jul 22, 2024Akash TewariJefferies$77.00$50.6152.14%116.11%
Jul 22, 2024Salveen RichterGoldman Sachs$33.00$50.61-34.80%-7.38%
Jul 16, 2024Akash TewariJefferies$75.00$49.8450.48%110.50%
Jun 27, 2024Paul MatteisStifel Nicolaus$53.00$47.7011.11%48.75%
Jun 17, 2024Luca IssiRBC Capital$70.00$40.6372.29%96.46%
Jun 14, 2024William PickeringTudor Pickering$44.00$41.127.00%23.49%
May 17, 2024Kostas BiliourisBMO Capital$67.00$36.8481.87%88.04%
Feb 03, 2023Leerink Partners$34.00$41.20-17.48%-4.57%
Dec 21, 2022Morgan Stanley$40.00$38.922.77%12.26%
Aug 10, 2022Citigroup$28.00$44.46-37.02%-21.41%
Aug 10, 2022RBC Capital$64.00$44.4643.95%79.62%
Jun 21, 2022Do KimPiper Sandler$55.00$37.5646.43%54.36%
Jun 21, 2022Leerink Partners$27.00$37.36-27.73%-24.22%
May 09, 2022Morgan Stanley$30.00$34.25-12.41%-15.80%
Feb 24, 2022Joseph StringerNeedham$60.00$32.4984.67%68.40%
Feb 24, 2022Luca IssiRBC Capital$67.00$32.49106.22%88.04%
Feb 01, 2022Jason GerberryBank of America Securities$30.00$31.51-4.79%-15.80%
Nov 04, 2021Gena WangBarclays$33.00$34.63-4.71%-7.38%
Oct 18, 2021Yale JenLaidlaw$68.00$30.25124.79%90.85%
May 10, 2021Esther RajaveluUBS$37.50$36.243.48%5.25%
May 05, 2021Kevin DeGeeterOppenheimer$63.00$39.8957.93%76.82%

The latest Ionis Pharmaceuticals stock forecast, released on Oct 09, 2024 by Debjit Chattopadhyay from Guggenheim, set a price target of $65.00, which represents a 71.96% increase from the stock price at the time of the forecast ($37.80), and a 82.43% increase from IONS last price ($35.63).

Ionis Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts-110
Avg Price Target-$65.00$60.60
Last Closing Price$35.63$35.63$35.63
Upside/Downside-100.00%82.43%70.08%

In the current month, the average price target of Ionis Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ionis Pharmaceuticals's last price of $35.63. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 09, 2024GuggenheimBuyBuyHold
Sep 26, 2024RBC CapitalMarket PerformMarket PerformHold
Sep 26, 2024NeedhamUnderperformUnderperformHold
Aug 26, 2024NeedhamMarket PerformMarket PerformHold
Aug 02, 2024Wells FargoMarket PerformMarket PerformHold
Aug 02, 2024BMO CapitalOutperformMarket PerformDowngrade
Jul 24, 2024Leerink PartnersOutperformUpgrade
Jul 22, 2024JefferiesBuyBuyHold
Jul 22, 2024William BlairOutperformOutperformHold
Jul 22, 2024Goldman SachsSellSellHold
Jul 16, 2024NeedhamUnderperformUnderperformHold
Jul 16, 2024JefferiesBuyUpgrade
Jun 27, 2024OppenheimerUnderperformUnderperformHold
Jun 27, 2024Wells FargoBuyBuyHold
Jun 24, 2024Cowen & Co.BuyBuyHold
Jun 17, 2024RBC CapitalOutperformOutperformHold
Jun 14, 2024BernsteinMarket PerformUpgrade
Jun 03, 2024Wells FargoBuyBuyHold
May 31, 2024William BlairOutperformOutperformHold
May 17, 2024BMO CapitalOutperformOutperformHold
May 16, 2024Cowen & Co.BuyBuyHold
Apr 09, 2024Wolfe ResearchOutperformUpgrade
Apr 09, 2024Sandler O'NeillBuyBuyHold
Apr 09, 2024OppenheimerOutperformOutperformHold
Jan 22, 2024William BlairOutperformOutperformHold
Jan 18, 2024Piper SandlerBuyBuyHold
Oct 23, 2023Bank of America SecuritiesNeutralUpgrade
Jul 31, 2023CitigroupNeutralBuyUpgrade
May 04, 2023CitigroupSellNeutralUpgrade
Feb 23, 2023CFRAHoldUpgrade
Feb 21, 2023William BlairOutperformOutperformHold
Feb 03, 2023SVB LeerinkMarket PerformMarket PerformHold
Dec 21, 2022Morgan StanleyEqual-WeightDowngrade
Aug 10, 2022CitigroupSellSellHold
Aug 10, 2022RBC CapitalOutperformOutperformHold
Jun 21, 2022Piper SandlerOverweightOverweightHold
Jun 21, 2022SVB LeerinkMarket PerformMarket PerformHold
Feb 25, 2022SVB LeerinkMarket PerformMarket PerformHold

Ionis Pharmaceuticals's last stock rating was published by Guggenheim on Oct 09, 2024. The company gave IONS a "Buy" rating, the same as its previous rate.

Ionis Pharmaceuticals Financial Forecast

Ionis Pharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue---------$144.21M$188.41M$131.00M$152.00M$159.77M$133.79M$141.92M$440.01M$133.09M$125.75M$111.61M$290.28M$160.08M$145.54M$133.37M$493.68M$167.89M$163.81M$297.21M$144.42M$110.30M
Avg Forecast$214.02M$159.11M$151.64M$132.58M$141.72M$129.57M$156.09M$131.42M$174.12M$136.86M$140.44M$128.15M$160.13M$143.95M$140.54M$122.46M$275.55M$160.15M$129.16M$128.62M$274.46M$182.14M$148.87M$161.13M$407.05M$153.80M$145.31M$285.38M$433.26M$183.84M
High Forecast$263.17M$195.66M$186.47M$146.15M$192.46M$133.30M$157.96M$131.42M$207.03M$166.52M$172.70M$157.58M$196.90M$143.95M$140.54M$122.46M$275.55M$160.15M$129.16M$128.62M$274.46M$182.14M$148.87M$161.13M$407.05M$153.80M$145.31M$285.38M$519.91M$220.61M
Low Forecast$167.90M$124.82M$118.96M$102.14M$113.73M$125.84M$154.22M$131.42M$128.03M$121.42M$110.18M$100.53M$125.62M$143.95M$140.54M$122.46M$275.55M$160.15M$129.16M$128.62M$274.46M$182.14M$148.87M$161.13M$407.05M$153.80M$145.31M$285.38M$346.61M$147.07M
# Analysts333514974915991313131377779999131313131515
Surprise %---------1.05%1.34%1.02%0.95%1.11%0.95%1.16%1.60%0.83%0.97%0.87%1.06%0.88%0.98%0.83%1.21%1.09%1.13%1.04%0.33%0.60%

Ionis Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 9 analysts is $174.12M, with a low forecast of $128.03M, and a high forecast of $207.03M. IONS's average Quarter revenue forecast represents a 20.75% increase compared to the company's last Quarter revenue of $144.21M (Sep 23).

Ionis Pharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts333514974915991313131377779999131313131515
EBITDA---------$-143.26M$-90.19M$-97.00M$-358.00M$-50.69M$-94.06M$-53.74M$227.09M$-76.73M$-73.18M$-83.38M$-6.42M$-12.52M$-17.08M$-36.38M$236.16M$26.93M$8.69M$130.63M$12.34M$17.20M
Avg Forecast$-19.77M$-14.70M$-14.01M$-12.25M$-13.09M$-11.97M$-14.42M$-109.83M$-16.08M$-12.64M$-12.97M$-99.85M$-14.79M$-37.47M$-36.58M$-78.93M$-71.73M$-41.69M$-33.62M$-64.14M$-71.44M$-47.41M$-38.75M$-33.35M$-105.96M$-40.03M$-37.83M$123.99M$18.51M$21.68M
High Forecast$-15.51M$-11.53M$-10.99M$-9.43M$-10.51M$-11.62M$-14.25M$-87.87M$-11.83M$-11.22M$-10.18M$-79.88M$-11.60M$-37.47M$-36.58M$-63.14M$-71.73M$-41.69M$-33.62M$-51.31M$-71.44M$-47.41M$-38.75M$-26.68M$-105.96M$-40.03M$-37.83M$148.79M$22.21M$26.01M
Low Forecast$-24.31M$-18.07M$-17.22M$-13.50M$-17.78M$-12.31M$-14.59M$-131.80M$-19.12M$-15.38M$-15.95M$-119.82M$-18.19M$-37.47M$-36.58M$-94.72M$-71.73M$-41.69M$-33.62M$-76.97M$-71.44M$-47.41M$-38.75M$-40.02M$-105.96M$-40.03M$-37.83M$99.19M$14.81M$17.34M
Surprise %---------11.33%6.95%0.97%24.20%1.35%2.57%0.68%-3.17%1.84%2.18%1.30%0.09%0.26%0.44%1.09%-2.23%-0.67%-0.23%1.05%0.67%0.79%

13 analysts predict IONS's average Quarter EBITDA for Mar 22 to be $-78.93M, with a high of $-63.14M and a low of $-94.72M. This is -134.76% lower than Ionis Pharmaceuticals's previous annual EBITDA (Dec 21) of $227.09M.

Ionis Pharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts333514974915991313131377779999131313131515
Net Income---------$-147.41M$-85.29M$-124.00M$-52.00M$-46.99M$-105.14M$-65.17M$224.61M$-82.47M$-80.88M$-89.87M$-340.27M$-30.94M$-31.84M$-48.23M$184.42M$26.16M$-876.00K$84.44M$-1.42M$3.47M
Avg Forecast$-124.96M$-151.38M$-158.03M$-164.27M$-161.54M$-167.27M$-137.46M$-122.61M$-118.95M$-149.83M$-131.20M$-111.46M$573.79M$-105.57M$-89.04M$-88.11M$-6.38M$-71.16M$-80.98M$-69.13M$37.77M$-18.93M$-37.73M$-44.21M$140.04M$-44.37M$-40.14M$80.15M$-2.13M$4.37M
High Forecast$-89.95M$-108.97M$-113.76M$-138.10M$-108.21M$-120.41M$-98.95M$-98.08M$-42.70M$-103.62M$-94.44M$-89.17M$688.54M$-105.57M$-89.04M$-70.49M$-6.38M$-71.16M$-80.98M$-55.30M$37.77M$-18.93M$-37.73M$-35.37M$140.04M$-44.37M$-40.14M$96.18M$-1.70M$5.24M
Low Forecast$-162.27M$-196.57M$-205.21M$-199.16M$-200.75M$-217.21M$-178.50M$-147.13M$-175.38M$-175.03M$-170.37M$-133.75M$459.03M$-105.57M$-89.04M$-105.73M$-6.38M$-71.16M$-80.98M$-82.96M$37.77M$-18.93M$-37.73M$-53.05M$140.04M$-44.37M$-40.14M$64.12M$-2.56M$3.50M
Surprise %---------0.98%0.65%1.11%-0.09%0.45%1.18%0.74%-35.23%1.16%1.00%1.30%-9.01%1.63%0.84%1.09%1.32%-0.59%0.02%1.05%0.67%0.79%

Ionis Pharmaceuticals's average Quarter net income forecast for Mar 22 is $-88.11M, with a range of $-105.73M to $-70.49M. IONS's average Quarter net income forecast represents a -139.23% decrease compared to the company's last Quarter net income of $224.61M (Dec 21).

Ionis Pharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts333514974915991313131377779999131313131515
SG&A---------$69.95M$46.14M$46.00M$48.00M$34.40M$33.80M$34.10M$38.60M$30.10M$45.10M$57.10M$138.84M$68.45M$72.02M$74.99M$83.28M$60.04M$75.11M$68.22M$43.65M$13.68M
Avg Forecast$65.21M$48.48M$46.20M$40.39M$43.18M$39.48M$47.56M$64.16M$53.05M$41.70M$42.79M$58.33M$98.61M$43.86M$42.82M$46.11M$83.95M$48.79M$39.35M$43.92M$83.62M$55.49M$45.36M$68.74M$124.02M$46.86M$44.27M$64.75M$65.48M$17.23M
High Forecast$80.18M$59.61M$56.81M$44.53M$58.64M$40.61M$48.13M$76.99M$63.08M$50.73M$52.62M$69.99M$118.33M$43.86M$42.82M$55.33M$83.95M$48.79M$39.35M$52.71M$83.62M$55.49M$45.36M$82.49M$124.02M$46.86M$44.27M$77.70M$78.58M$20.68M
Low Forecast$51.15M$38.03M$36.24M$31.12M$34.65M$38.34M$46.99M$51.33M$39.01M$36.99M$33.57M$46.66M$78.88M$43.86M$42.82M$36.89M$83.95M$48.79M$39.35M$35.14M$83.62M$55.49M$45.36M$55.00M$124.02M$46.86M$44.27M$51.80M$52.38M$13.79M
Surprise %---------1.68%1.08%0.79%0.49%0.78%0.79%0.74%0.46%0.62%1.15%1.30%1.66%1.23%1.59%1.09%0.67%1.28%1.70%1.05%0.67%0.79%

Ionis Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $53.05M, based on 9 Wall Street analysts, with a range of $39.01M to $63.08M. The forecast indicates a -24.16% fall compared to IONS last annual SG&A of $69.95M (Sep 23).

Ionis Pharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts333514974915991313131377779999131313131515
EPS---------$-1.03$-0.60$-0.87$-0.37$-0.33$-0.74$-0.46$1.59$-0.58$-0.57$-0.64$-2.44$-0.22$-0.23$-0.35$1.31$0.19$-0.01$0.63$-0.01$0.03
Avg Forecast$-0.84$-1.02$-1.06$-1.11$-1.09$-1.13$-0.93$-1.04$-0.80$-1.01$-0.88$-0.87$-0.94$-0.72$-0.61$-0.69$-0.04$-0.49$-0.55$-0.51$0.26$-0.13$-0.26$-0.14$0.96$-0.30$-0.28$0.61$-0.05$0.06
High Forecast$-0.61$-0.73$-0.77$-0.93$-0.73$-0.81$-0.67$-0.75$-0.29$-0.70$-0.64$-0.63$-0.68$-0.72$-0.61$-0.69$-0.04$-0.49$-0.55$-0.51$0.26$-0.13$-0.26$-0.14$0.96$-0.30$-0.28$0.61$-0.04$0.08
Low Forecast$-1.09$-1.32$-1.38$-1.34$-1.35$-1.46$-1.20$-1.35$-1.18$-1.18$-1.15$-1.13$-1.22$-0.72$-0.61$-0.69$-0.04$-0.49$-0.55$-0.51$0.26$-0.13$-0.26$-0.14$0.96$-0.30$-0.28$0.61$-0.05$0.05
Surprise %---------1.02%0.68%1.00%0.39%0.46%1.21%0.67%-36.40%1.19%1.03%1.26%-9.43%1.70%0.89%2.58%1.37%-0.63%0.04%1.04%0.20%0.50%

According to 13 Wall Street analysts, Ionis Pharmaceuticals's projected average Quarter EPS for Mar 22 is $-0.69, with a low estimate of $-0.69 and a high estimate of $-0.69. This represents a -143.22% decrease compared to IONS previous annual EPS of $1.59 (Dec 21).

Ionis Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
VKTXViking Therapeutics$46.70$97.80109.42%Buy
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
AKROAkero Therapeutics$30.61$50.0063.35%Buy
IOVAIovance Biotherapeutics$7.81$12.4058.77%Buy
IONSIonis Pharmaceuticals$37.68$58.3354.80%Buy
SRPTSarepta Therapeutics$125.76$187.2048.85%Buy
BMRNBioMarin Pharmaceutical$67.19$94.4340.54%Buy
INCYIncyte$69.40$90.1129.84%Buy
ALNYAlnylam Pharmaceuticals$246.58$310.6025.96%Buy
ARWRArrowhead Pharmaceuticals$22.27$27.7424.56%Buy
KRYSKrystal Biotech$169.04$210.3324.43%Buy
HALOHalozyme Therapeutics$48.60$52.007.00%Buy
MDGLMadrigal Pharmaceuticals$306.08$315.753.16%Buy
PTCTPTC Therapeutics$47.02$48.002.08%Hold
EXELExelixis$34.69$30.89-10.95%Buy

IONS Forecast FAQ

Is Ionis Pharmaceuticals a good buy?

Yes, according to 18 Wall Street analysts, Ionis Pharmaceuticals (IONS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 50.00% of IONS's total ratings.

What is IONS's price target?

Ionis Pharmaceuticals (IONS) average price target is $58.33 with a range of $33 to $77, implying a 63.71% from its last price of $35.63. The data is based on 18 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Ionis Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for IONS stock, the company can go up by 63.71% (from the last price of $35.63 to the average price target of $58.33), up by 116.11% based on the highest stock price target, and down by -7.38% based on the lowest stock price target.

Can Ionis Pharmaceuticals stock reach $50?

IONS's average twelve months analyst stock price target of $58.33 supports the claim that Ionis Pharmaceuticals can reach $50 in the near future.

What are Ionis Pharmaceuticals's analysts' financial forecasts?

Ionis Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $558.81M (high $615.14M, low $525.22M), average EBITDA is $-149M (high $-124M, low $-176M), average net income is $-589M (high $-426M, low $-744M), average SG&A $194.37M (high $224.36M, low $171.3M), and average EPS is $-4.174 (high $-2.95, low $-5.359). IONS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $657.36M (high $791.45M, low $513.83M), average EBITDA is $-60.72M (high $-47.462M, low $-73.106M), average net income is $-599M (high $-451M, low $-763M), average SG&A $200.28M (high $241.13M, low $156.55M), and average EPS is $-4.029 (high $-3.034, low $-5.136).

Did the IONS's actual financial results beat the analysts' financial forecasts?

Based on Ionis Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $587M, beating the average analysts forecast of $567.08M by 3.51%. Apple's EBITDA was $-561M, beating the average prediction of $-168M by 234.37%. The company's net income was $-270M, missing the average estimation of $291.06M by -192.77%. Apple's SG&A was $151M, missing the average forecast of $231.39M by -34.74%. Lastly, the company's EPS was $-1.9, missing the average prediction of $-2.96 by -35.82%. In terms of the last quarterly report (Sep 2023), Ionis Pharmaceuticals's revenue was $144.21M, beating the average analysts' forecast of $136.86M by 5.37%. The company's EBITDA was $-143M, beating the average prediction of $-12.642M by 1033.24%. Ionis Pharmaceuticals's net income was $-147M, missing the average estimation of $-150M by -1.61%. The company's SG&A was $69.95M, beating the average forecast of $41.7M by 67.76%. Lastly, the company's EPS was $-1.03, beating the average prediction of $-1.008 by 2.15%